Merck in $3.85B deal to acquire Cambridge's Idenix for its hepatitis C treatments

Drug giant Merck & Co. is planning to buy Cambridge biotech firm Idenix Pharmaceuticals for $3.85 billion, triple the local company's per-share price as of Friday’s close...